Filing Flows › Cardlytics (CDLX) › Q1 2025
Cardlytics (CDLX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Cardlytics (CDLX) reported revenue of $61.9M for the first quarter 2025 (Q1 2025), -8% from a year earlier and -16% from the quarter before. Operating margin was -22.7%, net loss $13.3M (21.5% of revenue).
Cardlytics, Q1 2025: revenue $61.9M (-8% year over year), operating margin -22.7%, net loss $13.3M, operating cash flow −$6.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $61.9M | -16% | -8% |
| Operating profit | −$14.1M | — | — |
| Net earnings | −$13.3M | — | — |
| Operating cash flow | −$6.7M | — | — |
What changed
Revenue was $61.9M in Q1 2025, down 8% year over year and down 16% from the previous quarter. Engagement based pricing was the largest line at 50% of revenue. Served based pricing lost $15.1M year over year (down 38%), 265% of the total change.
Operating costs exceeded revenue by $14.1M, an operating margin of -22.7%. Total costs fell 16% while revenue fell 8%. The quarter ended with a net loss of $13.3M, narrower than the previous quarter's $15.6M loss.
Operating cash flow was −$6.7M. Non-cash charges added back $6.3M of depreciation and amortization and $8.7M of share-based compensation. Working capital and other items used $8.4M. Capital expenditures of $119K exceeded it, leaving free cash flow of −$6.8M.
Questions
What was Cardlytics' revenue in the first quarter 2025?
Cardlytics (CDLX) reported revenue of $61.9M for the first quarter 2025 (Q1 2025), -8% from a year earlier and -16% from the quarter before.
Was Cardlytics profitable in the first quarter 2025?
Operating loss was $14.1M (-22.7% of revenue) and net loss $13.3M.
Source: Cardlytics 10-Q on SEC EDGAR.